CHATSWORTH, Calif., Oct. 26, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables, and a developer of high-value personalized diagnostics tests, today announced that its IRIS Molecular Diagnostics subsidiary has received ISO 13485:2003 certification and Conformité Européenne (CE) Mark for its NADiA® ProsVue™ prognostic cancer test.
